View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
June 17, 2014

PowerVision completes $30m Series D financing round for FluidVision lens development

US-based medical device company PowerVision has announced the completion of a $30m Series D financing round to fund development of its FluidVision accommodating intraocular lens.

By Mekala ShivaramPrasad

US-based medical device company PowerVision has announced the completion of a $30m Series D financing round to fund development of its FluidVision accommodating intraocular lens.

In the Series D financing round, new investors Aisling Capital and Correlation Venture Partners, as well as existing investor, Venrock, added $10m to the $20m closing earlier 2014 from PowerVision’s existing investors.

PowerVision will use the proceeds of the funding to complete patient enrolment in the ongoing CE Mark study of the FluidVision accommodating intraocular lens.

"Current treatment methods fall short, and most patients must still rely on reading glasses or other corrective lenses to see both near and far."

Patient enrolment is expected to be completed by the end of this year, while receipt of the CE Mark approval and subsequent launch of the US pivotal study coming in 2015.

The company’s major investors now include Aisling Capital, Correlation Ventures, Advanced Technology Ventures, Frazier Healthcare, Venrock, Johnson & Johnson Development, and Medtronic.

PowerVision has developed the FluidVision lens to permanently restore clear vision at all distances for patients affected by presbyopia or cataracts.

FluidVision lenses provide mimic the eye’s natural accommodative process to change shape and adjust focus the way that young, healthy eyes do.

PowerVision president, CEO and co-founder Barry Cheskin said: "Current treatment methods fall short, and most patients must still rely on reading glasses or other corrective lenses to see both near and far.

"The FluidVision lens would eliminate that need, and could provide a new option for millions of people with these conditions."

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU